Title:COL10A1 as a Prognostic Biomarker in Association with Immune Infiltration
in Prostate Cancer
Volume: 24
Issue: 3
关键词:
X α 1型胶原蛋白，前列腺癌，预后，免疫浸润，生物标志物，COL10A1。
摘要:
Background: The collagen type X alpha 1 (COL10A1) has recently been found to play
an important role in the development and progression of cancer. However, the link between
COL10A1 and the tumor immune microenvironment remains understood scantily.
Methods: In the current study, the pan-cancer data of The Cancer Genome Atlas (TCGA) and
Gene Expression Omnibus (GEO) were used to investigate the expression mode, the clinical prognostic
and diagnostic value of COL10A1 in different tumors. We used TCGA data to assess the correlations
between COL10A1 and clinical symptoms of prostate cancer. The R packages “edgR” and
“clusterProfiler” were used for differential expression gene and enrichment analysis of COL10A1.
Immunohistochemistry was further employed to corroborate the expression of COL10A1 gene in
prostate cancer. After that, we used TIMER to evaluate the pertinence of COL10A1 expression to
immune infiltration level in prostate cancer.
Results: On the whole, COL10A1 was expressed at significantly higher levels in a variety of tumor
tissues than in the corresponding normal tissues. Besides, significant correlations with tumor prognosis
and relative exactitude in predicting tumors show that COL10A1 may be a probable prognostic
and diagnostic biomarker of prostate cancer. In addition, the evidence indicates a significant correlation
between COL10A1 and clinical symptoms of prostate cancer. Furthermore, the main molecular
functions of COL10A1 included humoral immune response, complement activation, immunoglobulin,
regulation of complement activation, and regulation of humoral immune response. Finally,
we found that COL10A1 expression is positively correlated with enhanced macrophage and M2
macrophage infiltration in prostate cancer.
Conclusion: The study indicates that COL10A1 might participate in M2 macrophage polarization
in prostate cancer. COL10A1 might be an innovative biomarker to evaluate tumor microenvironment
immune cell infiltration and prognosis in prostate cancer.
